Skip to content

Blog

Author: Scientific Office

<a href="https://www.bioagilytix.com/blog/category/biomarkers/">Biomarkers</a>

C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification

  • August 13, 2019

A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioanalytical-platforms/">Bioanalytical Platforms</a>

Platform Spotlight: ImmunoCAP to Support Diagnosis of Allergic Reactions Against Biologics

  • July 25, 2019

The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/immunogenicity/">Immunogenicity</a>

Immunogenicity Assessment Using the Biacore™ T200 SPR System

  • July 18, 2019

What are the advantages of using the Biacore™ T200 SPR System for immunogenicity assessments with a tiered approach? Our experts discuss.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?

  • July 11, 2019

The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cro-selection/">CRO Selection</a>

To the Rescue: Applying a Novel Approach to Minimize False Positive ADA Assay Results

  • July 2, 2019

Target interference can cause false positive ADA assay results and stall out promising drugs. This could have been the case for one study involving an…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

BioAgilytix Team Q&A: Meet Mike Losauro, Senior Business Development Director at BioAgilytix

  • June 20, 2019

Did you know that many of our team members have cross-functional background experience both in the lab and in customer-facing roles, making them uniquely equipped…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Your Questions About Immunogenicity Assessment of Gene Therapy Compounds Answered

  • June 14, 2019

The webinar I recently hosted with my colleague Lydia Michaut explored key challenges and trends in the immunogenicity assessment of gene therapy compounds. This recap…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

A History of Gene Therapy: Exploring Lessons Learned In Light of New Approvals

  • June 4, 2019

The FDA recently approved the first gene therapy for pediatric patients with SMA, signifying a major step forward for the therapeutic field as a whole.…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Key Takeaways from the 13th Annual WRIB, 2019

  • May 17, 2019

Last month at WRIB, our scientific team had the opportunity to participate in a number of discussions surrounding the latest topics of interest in biomarkers,…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Immunogenicity Assessment of Gene Therapy Compounds

  • May 10, 2019

By Dr. Arno Kromminga and Dr. Lydia Michaut

Gene therapy has experienced an exciting resurgence in the post-genomic era, but unwanted immunogenicity is still a…

Find Out More